Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. - Wikidata - wikimedia - TriplyDB

Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.

Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.

http://www.wikidata.org/entity/Q34617924

about

Androgen receptor (AR) in cardiovascular diseases Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States.Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer Clinical utility of denosumab for treatment of bone loss in men and women Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.

P2860

Q26771962-2D346A1C-30B9-4CA7-A12D-A9CA4BD56391 Q30549679-A0577B62-D3BA-4E12-87DF-3268BF3DC998 Q34617904-70F9DE71-4964-413B-9222-00F351B7CD09 Q35092799-A1B1F2C7-C3DE-47C1-97BA-62A734045515 Q36900784-34E68FBD-E39C-4DB5-986D-C2C1D4FA9913 Q39247489-C3BC1F55-7338-492C-AD64-B75FA835880B Q42214667-9E73371B-8D6F-4181-AE2D-71744535BD4D Q49971559-49C8577E-164C-4A12-96D2-42F57B18D0D5

P2860

Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.

http://www.wikidata.org/entity/Q34617924

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Androgen deprivation therapy a ...... in prostate cancer survivors.

@ast

Androgen deprivation therapy a ...... in prostate cancer survivors.

@en

Androgen deprivation therapy a ...... in prostate cancer survivors.

@nl

type

label

Androgen deprivation therapy a ...... in prostate cancer survivors.

@ast

Androgen deprivation therapy a ...... in prostate cancer survivors.

@en

Androgen deprivation therapy a ...... in prostate cancer survivors.

@nl

prefLabel

Androgen deprivation therapy a ...... in prostate cancer survivors.

@ast

Androgen deprivation therapy a ...... in prostate cancer survivors.

@en

Androgen deprivation therapy a ...... in prostate cancer survivors.

@nl

P1433

Q34617924-698BA449-574F-4D1E-AA6F-291023FF9A85

P1476

Q34617924-AE25C022-F67A-4A5D-89FC-FE629E9AE8A9

P2093

Q34617924-9DD95815-7412-4A99-929D-B23597FB1CC3

P2860

Q34617924-00D002BE-CE92-482B-B2C9-B10889CC1665

Q34617924-1B26175D-C479-4128-ADAE-300A5529C378

Q34617924-1BC5640C-B403-4B9A-AE6B-8969088E2B81

Q34617924-26CADA86-FFA4-43B9-A727-B30DFCA26E4B

Q34617924-433F12CB-83CC-4E67-8363-FC314664F9DE

Q34617924-4817D581-ADA1-445D-8835-18F117510DFF

Q34617924-4BB90B12-A551-41FC-80FF-25A49441FB6D

Q34617924-4BD68BDC-5E68-40FF-A3FF-EDA8BD0CE84B

Q34617924-53599AA3-3846-403F-83C0-8420E4F3CF0C

Q34617924-5F5B00E1-CA04-4AA4-A118-48752C6CE818

P2888

Q34617924-48F04598-EF19-4715-A6E4-004D6FA14CDD

P304

Q34617924-88031007-1B9D-4337-B577-1601F5DAAE9D

P31

Q34617924-AEFF6FC9-4E8F-40A5-BA51-723D244E4F4A

Q34617924-f313ebe1-8e2c-4d85-8274-73df74e2838f

P356

Q34617924-F2E58CA9-B0B3-4DC9-9F3C-270E2A49DE5B

P433

Q34617924-AE2EF911-4BD4-4E8C-82A5-D49173A59A80

P478

Q34617924-F2B2C77F-3DD8-43B7-B3AC-8529FAC45CED

P577

Q34617924-E3DF3109-50E6-4021-A8FE-741ADFC976D4

P5875

Q34617924-70C4A1DE-433E-4598-B1A5-353DA179E63A

P6179

Q34617924-8903EDBA-F98E-40D4-8C14-C671DFDA5D2D

P698

Q34617924-3221D092-E043-4686-B7F1-6309D694D58D

P921

Q34617924-8B4E7E9A-159C-435E-9092-AFD968ADFD12

P932

Q34617924-CC787921-AFE7-4EDD-8475-D9A4AA164520

P356

S11934-008-0035-Y

P1433

Current urology reports

P1476

Androgen deprivation therapy a ...... in prostate cancer survivors.

@en

P2093

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

Testosterone, body composition and aging.

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

National practice patterns and time trends in androgen ablation for localized prostate cancer.

Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

Androgen deprivation therapy for prostate cancer.

P2888

s11934-008-0035-y

P304

197-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11934-008-0035-Y

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23231359

http://www.w3.org/2001/XMLSchema#string

P6179

1004415419

http://www.w3.org/2001/XMLSchema#string

P698

18765113

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

3047401

http://www.w3.org/2001/XMLSchema#string